The Potential of Cannabidiol as a Treatment for Psychosis and Addiction : Who Benefits Most ? A Systematic Review Albert Batalla, Hella Janssen, Shiral S. Gangadin and Matthijs G. Bossong Journal of Clinical Medicine, 2019, 8, 1058 doi : 10.3390/jcm8071058 Abstract : The endogenous cannabinoid (eCB) system plays an important role in the pathophysiology of both psychotic disorders and substance use disorders (SUDs). The non-psychoactive cannabinoid compound, cannabidiol (CBD) is a highly promising tool in the treatment of both disorders. Here we review human clinical studies that investigated the ecacy of CBD treatment for schizophrenia, substance use disorders, and their comorbidity. In particular, we examined [...]
Lire la suiteNabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence : A pilot randomized clinical trial Jose M. Trigo, Alexandra Soliman, Lena C. Quilty, Benedikt Fischer, JuÈrgen Rehm, Peter Selby, Allan J. Barnes11¤a, Marilyn A. Huestis, Tony P. George, David L. Streiner, Gregory Staios, Bernard Le Foll PLoS ONE, 2018, 13, (1), e0190768. https://doi.org/10.1371/journal.pone.0190768 Abstract Background The current lack of pharmacological treatments for cannabis use disorder (CUD) warrants novel approaches and further investigation of promising pharmacotherapy. We previously showed that nabiximols (27 mg/ml Δ9-tetrahydrocannabinol (THC)/ 25 mg/ml cannabidiol (CBD), Sativex®) can decrease cannabis withdrawal symptoms. Here, we assessed in a pilot study the [...]
Lire la suiteAnandamide administration alone and after inhibition of fatty acid amide hydrolase (FAAH) increases dopamine levels in the nucleus accumbens shell in rats Marcello Solinas, Zuzana Justinova, Steven R. Goldberg and Gianluigi Tanda Journal of Neurochemistry, 2006, 98, 408–419. doi:10.1111/j.1471-4159.2006.03880.x Abstract Although endogenous cannabinoid systems have been implicated in the modulation of the rewarding effects of abused drugs and food, little is known about the direct effects of endogenous ligands for cannabinoid receptors on brain reward processes. Here we show for the first time that the intravenous administration of anandamide, an endogenous ligand for cannabinoid receptors, and its longer-lasting synthetic analog methanandamide, increase the extracellular dopamine [...]
Lire la suitePsychedelic Elephant A critique of psychedelic research Peter Webster juillet 2019 https://www.researchgate.net/search.Search.html?type=researcher&query=Psychedelic%20Elephant My title might lead some who are old enough to remember the incident 1 2 to expect from this essay an indictment of the idiots who conducted the "scientific research" during which an elephant was clearly murdered.3 It is always great fun to expose foolishness and willful ignorance. But unfortunately, psychedelic research in those days, the 1950s and 1960s, attracted no small number of other scientists who, at least in retrospect, could also be called idiots. Jean Houston (1967) has described one of her initial observations of LSD administration. The subject was told by [...]
Lire la suiteIntegrating Psychedelic Medicines and Psychiatry : Theory and Methods of a Model Clinic Jordan Sloshower Chapter 7, In : Labate B., Cavnar C. (eds) : Plant Medicines, Healing and Psychedelic Science, 2018 © Springer International Publishing AG 2018 DOI: 10.1007/978-3-319-76720-8_7 Abstract The past two decades has seen a significant increase in both popular and scientific interest in psychedelic substances and plants as therapeutics for mental illness, addictions, and psychospiritual suffering. Current psychiatric practice privileges a biological paradigm in which the brain is considered the locus of mental illness and symptom-focused treatments are delivered to patients as passive recipients. In contrast, a psychedelic healing paradigm, constructed through [...]
Lire la suiteExpanding the Scientific Study of Self-Experience with Psychedelics Manesh Girn and Kalina Christoff Journal of Consciousness Studies, 2018, 25, (11–12), 131–54 Abstract : The nature of the self has long been a topic of discussion in philosophical and religious contexts, and has recently also garnered significant scientific attention. Although evidence exists to suggest the multifaceted nature of self-experience, the amount of research done on each of its putative components has not been uniform. Whereas selfreflective processing has been studied extensively, non-reflective aspects of self-experience have been the subject of comparatively little empirical research. This discrepancy may be linked to the methodological difficulties in experimentally [...]
Lire la suiteThe Influence of Psychedelic Induced Ego-Dissolution on Self-Compassion, Kevin Allan Stansbury, 2019
The Influence of Psychedelic Induced Ego-Dissolution on Self-Compassion Kevin Allan Stansbury B.A., 2011, California State University, Dominguez Hills, May 2019 A THESIS Presented to the School of Social Work California State University, Long Beach In Partial Fulfillment of the Requirements for the Degree Master of Social Work Abstract Prior research has shown that psychedelic induced ego-dissolution mediates therapeutic outcomes and enhances well-being. The experience of psychedelics has been shown to increase certain mindfulness capacities. A cross-sectional descriptive study was implemented in an online community to examine the relationship between psychedelic induced ego-dissolution and self-compassion in adults who have used psychedelics in the past. This study also [...]
Lire la suitePsychedelic drug use in healthy individuals : a review of benefits, costs, and implications for drug policy James W.B. Elsey Drug Science, Policy and Law, 2017, Vol 3, 1-11 DOI: 10.1177/2050324517723232 Abstract The potential of psychedelic drugs in the treatment of mental health problems is increasingly being recognized. However, relatively little thrust has been given to the suggestion that individuals without any mental health problems may benefit from using psychedelic drugs, and that they may have a right to do so. This review considers contemporary research into the use of psychedelic drugs in healthy individuals, including neurobiological and subjective effects. In line with findings [...]
Lire la suitePsilocybin – Summary of knowledge and new perspectives Filip Tylš, Tomáš Páleníček, Jiří Horáček European Neuropsychopharmacology, 2014, 24, 342–356 Doi : 10.1016/j.euroneuro.2013.12.006 Abstract Psilocybin, a psychoactive alkaloid contained in hallucinogenic mushrooms, is nowadays given a lot of attention in the scientific community as a research tool for modeling psychosis as well as due to its potential therapeutic effects. However, it is also a very popular and frequently abused natural hallucinogen. This review summarizes all the past and recent knowledge on psilocybin. It briefly deals with its history, discusses the pharmacokinetics and pharmacodynamics, and compares its action in humans and animals. It attempts to describe the mechanism of psychedelic effects [...]
Lire la suiteEffects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditionning CATLOW B.J., SONG S., PAREDES D.A., KIRSTEIN C.L., SANCHEZ-RAMOS J. Experimental Brain Research, 2013, 228, 481-491. Doi : 10.1007/s00221-013-3579-0 Abstract Drugs that modulate serotonin (5-HT) synaptic concentrations impact neurogenesis and hippocampal (HPC)-dependent learning. The primary objective is to determine the extent to which psilocybin (PSOP) modulates neurogenesis and thereby affects acquisition and extinction of HPC-dependent trace fear conditioning. PSOP, the 5-HT2A agonist 25I-NBMeO and the 5-HT2A/C antagonist ketanserin were administered via an acute intraperitoneal injection to mice. Trace fear conditioning was measured as the amount of time spent immobile in the presence of the conditioned [...]
Lire la suite